Holen Sie sich die Stockscreener-App
72.08
1.21%
-0.88
Handel nachbörslich:
72.23
0.15
+0.21%
Schlusskurs vom Vortag:
$72.96
Offen:
$73.65
24-Stunden-Volumen:
1.02M
Relative Volume:
0.95
Marktkapitalisierung:
$2.07B
Einnahmen:
$55.23M
Nettoeinkommen (Verlust:
$-164.08M
KGV:
-10.53
EPS:
-6.8461
Netto-Cashflow:
$-208.68M
1W Leistung:
-1.50%
1M Leistung:
+2.43%
6M Leistung:
+29.59%
1J Leistung:
+8,509%
1-Tages-Spanne:
$70.86
$77.97
1-Wochen-Bereich:
$70.67
$77.97
52-Wochen-Spanne:
$0.432
$77.97
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
72.08 | 2.09B | 55.23M | -164.08M | -208.68M | -6.8461 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | TD Cowen | Buy |
| 2026-02-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Eingeleitet | Citigroup | Buy |
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) ... - Bluefield Daily Telegraph
Nektar Therapeutics stock hits 52-week high at 77.36 USD By Investing.com - Investing.com Australia
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week HighHere's Why - MarketBeat
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards - marketscreener.com
Wedbush initiates coverage of Nektar Therapeutics (NKTR) with neutral recommendation - MSN
Wedbush Initiates Coverage on Nektar Therapeutics (NKTR) with Ne - GuruFocus
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - GlobeNewswire Inc.
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures - TipRanks
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated by Analysts at Wedbush - MarketBeat
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit — The Gross Law Firm - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Wedbush initiates Nektar Therapeutics stock with neutral rating By Investing.com - Investing.com Australia
Wedbush initiates Nektar Therapeutics stock with neutral rating - Investing.com
Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead - GlobeNewswire
Wedbush Initiates Nektar Therapeutics at Neutral With $70 Price Target - marketscreener.com
Wedbush Starts Nektar Therapeutics (NKTR) at Neutral - StreetInsider
Nektar Therapeutics Faces High-Stakes AAD Data Test as Sky-High Valuation Leaves Little Room for Error - Bitget
A Look At Nektar Therapeutics (NKTR) Valuation As Rezpegaldesleukin Data Heads To Major Dermatology Meeting - simplywall.st
Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action - PR Newswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
Nektar Therapeutics stock is trending Tuesday: What's going on? - MSN
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire
Apogee strengthens case for longer-lasting eczema drug - BioPharma Dive
Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections - statnews.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
2 Healthcare Stocks to Buy Before They Get Bought Out - AOL.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionNKTR - ACCESS Newswire
NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
Hudson Bay Capital Management LP Purchases Shares of 107,678 Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
Nektar Q4 earnings & revenues trump estimates, pipeline in focus - MSN
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - The AI Journal
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm - WFXG
Nektar presents rezpegaldesleukin data at dermatology meeting - Investing.com
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Two skin and hair-loss studies from Nektar get oral AAD slots - Stock Titan
Abivax & Nektar Therapeutics: Clinical-Stage Biotech Drug Development in 2026News and Statistics - IndexBox
2 Healthcare Shares to Consider Purchasing Before Potential Buyouts - Bitget
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting - Sahm
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
How The Nektar Therapeutics (NKTR) Story Is Shifting Around Rezpeg And Fair Value Estimates - Yahoo Finance
B-Cell Lymphomas Clinical Trial Pipeline Appears Robust With 295+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NKTR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - TMX Newsfile
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):